IP Library Granted Patent US 11,542,253
Granted Patent B2
US 11,542,253 · App. 17/144,884 · Granted Jan 3, 2023

Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine

Inventors: Srinivasa Rao Akireddy (Winston-Salem, NC); Balwinder Singh Bhatti (Winston-Salem, NC); Timothy J. Cuthbertson (Winston-Salem, NC); Gary Maurice Dull (Lewisville, NC); Craig Harrison Miller (Winston-Salem, NC); Joseph Pike Mitchener, Jr. (Winston-Salem, NC); Julio A. Munoz (Walnut Cove, NC); Pieter Albert Otten (King, NC)
Assignee: Oyster Point Pharma, Inc.
C07D403/06A61K31/4025C07C59/255C07C59/265
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,542,253
App. No.
17/144,884
Granted
Jan 3, 2023
Kind
B2
Abstract

The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.

Claims (17)

1. A method for manufacture of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono citrate comprising:

(a) reacting compound 9, tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate, with 5-bromo-pyrimidine to give compound 10

(b) deprotecting compound 10 to give compound 11

(c) mixing the free base, or a solution of the free base, of compound 11 in a first solvent with citric acid in pure form or as a solution of the citric acid in a first solvent to form a citrate salt solution, wherein the first solvent is selected from the group consisting of ethanol, methanol, isopropyl alcohol, isopropyl acetate, acetone, ethyl acetate, toluene, water, methyl ethyl ketone, methyl isobutyl ketone, tert-butyl methyl ether, tetrahydrofuran, dichloromethane, n-heptane, and acetonitrile;

(d) (i) cooling the resulting citrate salt solution to cause precipitation; or

(d) (ii) adding a second solvent selected from the group consisting of ethanol, methanol, isopropyl alcohol, isopropyl acetate, acetone, ethyl acetate, toluene, water, methyl ethyl ketone, methyl isobutyl ketone, tert-butyl methyl ether, tetrahydrofuran, dichloromethane, n-heptane, and acetonitrile to cause precipitation; or

(d) (iii) evaporating the first solvent and adding a second solvent selected from the group consisting of ethanol, methanol, isopropyl alcohol, isopropyl acetate, acetone, ethyl acetate, toluene, water, methyl ethyl ketone, methyl isobutyl ketone, tert-butyl methyl ether, tetrahydrofuran, dichloromethane, n-heptane, and acetonitrile, and repeating either step (d) (i) or (d) (ii); and

(e) filtering to collect the (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate.

2. The method of claim 1 , wherein the reaction of step (a) is a palladium-catalyzed reaction.

3. The method of claim 2 , wherein the palladium-catalyzed reaction is performed with palladium acetate.

4. The method of claim 1 , wherein the reaction of step (a) is performed in N,N-dimethylacetamide.

5. The method of claim 1 , wherein the deprotection reaction of step (b) is performed with a reagent selected from the group consisting of trifluoroacetic acid, hydrochloric acid, and sulfuric acid.

6. The method of claim 5 , wherein the reagent is hydrochloric acid.

7. The method of claim 1 , wherein the first solvent for step (c) is methanol.

8. The method of claim 1 , wherein the second solvent for step (d)(ii) is methanol.

9. The method of claim 1 , wherein the first solvent for step (d)(iii) is methanol.

10. The method of claim 1 , wherein the second solvent for step (d)(iii) is methanol.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Feb 3, 2023
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: OYSTER POINT PHARMA INC.
Reel/Frame 062582/0873 →
PATENT SECURITY AGREEMENT Recorded Aug 5, 2021
From: OYSTER POINT PHARMA, INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057104/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2021
From: AKIREDDY, SRINIVASA RAO; BHATTI, BALWINDER SINGH; CUTHBERTSON, TIMOTHY J.; DULL, GARY MAURICE; MILLER, CRAIG HARRISON; MITCHENER, JOSEPH PIKE, JR.; MUNOZ, JULIO A.; OTTEN, PIETER ALBERT
To: TARGACEPT, INC.
Reel/Frame 054960/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2021
From: CATALYST BIOSCIENCES, INC.
To: OYSTER POINT PHARMA, INC.
Reel/Frame 054960/0591 →
CHANGE OF NAME Recorded Jan 11, 2021
From: TARGACEPT, INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 055226/0671 →
Continuity (8)
Continuation 16541033 · Aug 14, 2019
Continuation 15962982 · Apr 25, 2018
Continuation 15354832 · Nov 17, 2016
Continuation 14832030 · Aug 21, 2015
Continuation 14074147 · Nov 7, 2013
Continuation 13129898
Provisional Application 61118796 · Dec 1, 2008
Related Publication 20210371401A1 · Dec 2, 2021
Cited By (2)
US 12,576,080 US 12,653,824